Surgical treatment of oligometastatic nasopharyngeal carcinoma
Clinical Surgical Oncology · 2023
DOI: 10.1016/j.cson.2023.100018 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Surgical Oncology, 2023. Verfasst von Wendan Gong und 3 weiteren Autor:innen. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 68 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Oligometastasis-directed therapies have shown promise in improving patient outcomes. In this review, we summarized the current understanding of oligometastatic nasopharyngeal carcinoma (NPC) and the role of surgery in its management. Since the majority of clinical evidence supporting the benefit of surgical treatment on oligometastatic NPC is derived from non-controlled, single-arm, observational studies, therefore, findings reported before should be interpreted with caution and it is crucial to identify the right patients for oligometastasectomy to ensure the safety and effectiveness for patients. Future studies investigating the oligometastatic state should employ more robust study designs, such as randomized controlled trials, to guide clinical decision-making. Additionally, a comprehensive understanding of the tumor biology associated with oligometastatic NPC is necessary for developing effective treatment strategies for patients.
Zitieren
APA
Gong, W., Zheng, S., Yu, H., & Zhang, Z. (2023). Surgical treatment of oligometastatic nasopharyngeal carcinoma. Clinical Surgical Oncology. https://doi.org/10.1016/j.cson.2023.100018
Vancouver
Gong W, Zheng S, Yu H, Zhang Z. Surgical treatment of oligometastatic nasopharyngeal carcinoma. Clinical Surgical Oncology. 2023. doi:10.1016/j.cson.2023.100018
BibTeX
@article{Gong2023,
author = {Gong, Wendan and Zheng, Shixing and Yu, Hongmeng and Zhang, Zhe},
title = {Surgical treatment of oligometastatic nasopharyngeal carcinoma},
journal = {Clinical Surgical Oncology},
year = {2023},
doi = {10.1016/j.cson.2023.100018}
}
EUVIMED